ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Asks $955 Million In ’78; HEW Says $799 Will Be Enough

August 20, 1976

New Research Training Act May Permit NCI To Help fill Clinical Gaps In Radiotherapy, Medical Oncology

July 26, 1974

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002

Genetronics Phase II Trials For Head & Neck Completed.

May 4, 2001

“5 A Day” Review Underway to Check Program’s Health at NCI.

March 31, 2000

In Brief: Jay Moskowitz Reassigned; Healy To Run For Ohio Republican Nomination To Senate

September 17, 1993